Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation
- PMID: 12504810
- DOI: 10.1016/s0008-6363(02)00694-6
Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation
Abstract
The cardiac SR Ca(2+)-ATPase (SERCA2a) regulates intracellular Ca(2+)-handling and thus, plays a crucial role in initiating cardiac contraction and relaxation. SERCA2a may be modulated through its accessory phosphoprotein phospholamban or by direct phosphorylation through Ca(2+)/calmodulin dependent protein kinase II (CaMK II). As an inhibitory component phospholamban, in its dephosphorylated form, inhibits the Ca(2+)-dependent SERCA2a function, while protein kinase A dependent phosphorylation of the phospho-residues serine-16 or Ca(2+)/calmodulin-dependent phosphorylation of threonine-17 relieves this inhibition. Recent evidence suggests that direct phosphorylation at residue serine-38 in SERCA2a activates enzyme function and enhances Ca(2+)-reuptake into the sarcoplasmic reticulum (SR). These effects that are mediated through phosphorylation result in an overall increased SR Ca(2+)-load and enhanced contractility. In human heart failure patients, as well as animal models with induced heart failure, these modulations are altered and may result in an attenuated SR Ca(2+)-storage and modulated contractility. It is also believed that abnormalities in Ca(2+)-cycling are responsible for blunting the frequency potentiation of contractile force in the failing human heart. Advanced gene expression and modulatory approaches have focused on enhancing SERCA2a function via overexpressing SERCA2a under physiological and pathophysiological conditions to restore cardiac function, cardiac energetics and survival rate.
Similar articles
-
Targeting phospholamban by gene transfer in human heart failure.Circulation. 2002 Feb 26;105(8):904-7. doi: 10.1161/hc0802.105564. Circulation. 2002. PMID: 11864915 Free PMC article.
-
Sarcoplasmic reticulum Ca(2+)/Calmodulin-dependent protein kinase is altered in heart failure.Circ Res. 2000 Mar 17;86(5):596-605. doi: 10.1161/01.res.86.5.596. Circ Res. 2000. PMID: 10720422
-
Sarcoplasmic reticulum Ca2+ load in human heart failure.Basic Res Cardiol. 2002;97 Suppl 1:I63-71. doi: 10.1007/s003950200032. Basic Res Cardiol. 2002. PMID: 12479237
-
Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions.Cardiovasc Res. 2005 Dec 1;68(3):366-75. doi: 10.1016/j.cardiores.2005.08.010. Epub 2005 Oct 13. Cardiovasc Res. 2005. PMID: 16226237 Review.
-
Phospholamban and cardiac function: a comparative perspective in vertebrates.Acta Physiol (Oxf). 2012 May;205(1):9-25. doi: 10.1111/j.1748-1716.2012.02389.x. Acta Physiol (Oxf). 2012. PMID: 22463608 Review.
Cited by
-
Differences in MEF2 and NFAT transcriptional pathways according to human heart failure aetiology.PLoS One. 2012;7(2):e30915. doi: 10.1371/journal.pone.0030915. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363514 Free PMC article.
-
Differential effects of the peroxynitrite donor, SIN-1, on atrial and ventricular myocyte electrophysiology.J Cardiovasc Pharmacol. 2013 May;61(5):401-7. doi: 10.1097/FJC.0b013e31828748ca. J Cardiovasc Pharmacol. 2013. PMID: 23364607 Free PMC article.
-
Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue.J Gen Physiol. 2013 Jan;141(1):73-84. doi: 10.1085/jgp.201210837. J Gen Physiol. 2013. PMID: 23277475 Free PMC article.
-
Proinflammatory cytokines in heart failure: double-edged swords.Heart Fail Rev. 2010 Nov;15(6):543-62. doi: 10.1007/s10741-010-9168-4. Heart Fail Rev. 2010. PMID: 20405319 Review.
-
Advances in miR-132-Based Biomarker and Therapeutic Potential in the Cardiovascular System.Front Pharmacol. 2021 Nov 2;12:751487. doi: 10.3389/fphar.2021.751487. eCollection 2021. Front Pharmacol. 2021. PMID: 34795586 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous